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In mammalian cells, there is an extensive and continuous exchange of mitochondrial DNA (mtDNA) and its products between mitochondria.
This mitochondrial complementation prevents individuals from expression of respiration deficiency caused by mutant mtDNAs. Thus, the
presence of mitochondrial complementation does not support the generally accepted mitochondrial theory of aging, which proposes that
accumulation of somatic mutations in mtDNA is responsible for age-associated mitochondrial dysfunction. Moreover, the presence of
mitochondrial complementation enables gene therapy for mitochondrial diseases using nuclear transplantation of zygotes.
© 2006 Elsevier B.V. All rights reserved.Keywords: Mitochondrial theory of aging; Mitochondrial complementation; Mito-mice; mtDNA recombination; Gene therapy; Nuclear transplantation1. Introduction
Mitochondria are organelles producing 90% ormore of all the
energy made in the body by oxidative phosphorylation
(OXPHOS). Mammalian mitochondria contain a covalently
closed circular mitochondrial DNA (mtDNA) that is replicated
and expressed within the organellar system [1,2]. Mammalian
mtDNA contains 37 genes, encoding 13 proteins (all of which
are OXPHOS subunits), 22 tRNAs, and 2 rRNAs [3]. The
remaining mitochondrial OXPHOS proteins, the metabolic
enzymes, the DNA and RNA polymerases and the ribosomal
proteins are all encoded by nuclear genome. Individual cells
contain several thousand copies of mtDNA, and , in normal
individuals, nearly all of the mtDNA is thought to be identical (a
state termed “homoplasmy”). However, in some cases, espe-
cially in mitochondrial diseases, wild-type and variant mtDNAs
coexist at different levels (a state termed “heteroplasmy”).⁎ Corresponding author. Tel.: +81 298 53 6650; fax: +81 298 53 6614.
E-mail address: jih45@sakura.cc.tsukuba.ac.jp (J.-I. Hayashi).
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doi:10.1016/j.bbamcr.2006.03.001The mutation rate of mtDNA is about 10 times higher in
mtDNA than nuclear genome. There are three reasons for the
high mutation rate in mtDNA. The first is that mtDNA is
susceptible to reactive oxygen species (ROS)-induced damage
due to highly oxidative circumstances in mitochondria.
Mitochondria are the major cellular site of production of
ROS. It is estimated that 1–5% of the oxygen consumed in the
mitochondrial OXPHOS electron transport chain is converted to
ROS. mtDNA associated with the mitochondrial inner mem-
brane [4,5] is in close proximity to the ROS-generating electron
transport chain [6,7]. The second reason is that mtDNA has no
histone-like protection as nuclear genome, so that mtDNA is
susceptible to ROS or other chemical reagent. The final reason
is that mitochondria do not have significant repair systems.
These circumstances cause mtDNA to accumulate various
somatic mtDNA mutations in mitotic [8] and post-mitotic [9–
11] tissues. This fact and the abundant evidence that a decline in
the OXPHOS capacity of mitochondria occurs with aging in
skeletal muscles, heart, brain, liver, and other organs [12–19]
have given support to “the mitochondrial theory of aging”
[7,20–22]. It proposes that age-associated mitochondrial
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accumulation of somatic mutations in the mtDNA population.
However, the recent findings indicate that the exchange of
mtDNA and its products between mitochondria do not support
the mitochondrial theory of aging. This “mitochondrial
complementation” is a mitochondria-specific mechanism for
avoiding expression of pathogenic mutant mtDNA.
In the present review, we aim to summarize the knowledge of
mitochondrial complementation, and then describe gene
therapy model for mitochondrial diseases using mitochondrial
complementation.
2. Aging and mtDNA mutations
mtDNA-less (ρ°) cells are obtained by long-term treatment
of cells with ethidium bromide (EtBr) [23]. Cybrids isolated by
mtDNA transfer from mitochondrial disease patients to ρ° cells
were used to investigate whether mutant mtDNAs were
responsible for mitochondrial diseases [24]. This procedure
can exclude involvement of the nuclear genome in expression of
the mitochondrial dysfunction. mtDNA transfer from aged
subjects to ρ° cells is useful to examine whether mtDNA
mutations are responsible for age-related reduction in respira-
tory function.
The role of mtDNA and nuclear genome in human aging was
examined by their intercellular transfer using skin fibroblasts
and ρ° HeLa cells [25]. Human skin fibroblasts obtained from
16 donors of various ages (0–97 years) showed age-related
reductions in the activity of cytochrome c oxidase (COX). The
abnormality in mitochondria of the aged donors was attributable
to significant decrease in mitochondrial translation activity.
However, irrespective of whether the mtDNA population was
transferred from fibroblasts of aged or fetal donors, all the
cybrids showed similar activities of COX and mitochondrial
translation. This observation suggests that nuclear-recessive
mutations of factors involved in mitochondrial translation but
not mtDNA mutations are responsible for the age-related
respiration deficiency of human fibroblasts. This idea was
supported by another observation that showed the restoration of
respiratory function by nuclear transfer from ρ° HeLa cells to
fibroblasts of aged subjects [26].
The mtDNA transfer from post-mitotic and highly oxidative
tissues to ρ° cells was also carried out. The cybrids obtained by
mtDNA transfer from postmortem mouse brain preserved for 1
month at 4 °C to ρ° mouse cells showed complete recovery of
COX activity [27]. This observation suggests that mtDNA in
brain tissue can survive for 1 month after death. Thus, this
procedure was applied to autopsied human brain tissues from
aged patient with Alzheimer's disease [28]. The cybrids were
obtained by mtDNA transfer from autopsied brain tissues to ρ°
HeLa cells. In brain tissues and their cybrids, the presence of
pathogenic mutant mtDNAwas observed. However, the cybrids
restored mitochondrial respiration activity, suggesting the
functional integrity of mtDNA in brain tissues of aged patient
with Alzheimer's disease.
All of these observations obtained with mtDNA transfer
from mitotic and post-mitotic cells to ρ° cells suggest thatnuclear genome is responsible for the age-related decline of
OXPHOS capacity. Accumulation of various somatic mtDNA
mutations in tissues [8–11] would not have a causative role but,
rather, it would be one of the manifestations in aging.
3. Mitochondrial complementation
In fact, mutations in mtDNA accumulate with aging. Some
of them were the same mutations observed in patients with
mitochondrial diseases such as mitochondrial myopathy,
encephalopathy, lactic acidosis, and stroke-like episodes
(MELAS), chronic progressive external ophthalmoplegia
(CPEO) and Kearns–Sayre syndrome (KSS) [9–11]. However,
why these pathogenic mtDNA mutations do not lead to
respiration deficiency? One explanation for this question is
the presence of “mitochondrial complementation”. This is the
idea that mitochondria and mtDNA function as a single
dynamic cellular unit in living cells by the presence of
exchanging mtDNA and its products between mitochondria.
In addition to the classic kidney bean-shaped organelles,
mitochondria are frequently found as extended reticular
networks [29]. Moreover, timelapse microscopy of living cells
reveals that mitochondria undergo constant migration, fission
and fusion [30]. It was also observed that fused mitochondria
exchanged their matrix contents [31,32] and mitochondrial
fission and fusion activity declined with aging [33]. It is
supposed that free mixing of mitochondrial genetic components
throughout the mitochondrial network would protect mamma-
lian mitochondria from direct expression of respiration defects
caused by accumulated mtDNA mutations.
3.1. In vitro mitochondrial complementation
Exchange of mtDNA was observed by fusion of enucleated
HeLa cells with ρ° HeLa cells [34]. By visualizing mtDNAwith
DNA-binding dyes EtBr and 4′,6-diamidino-2-phenylindole
(DAPI), mtDNA was shown to spread rapidly to all mitochon-
dria in the cybrids. This observation suggests the presence of
mitochondrial fusion and subsequent diffusion of mtDNA. In
another experiment, cells possessing deletion mutant mtDNA
and HeLa cells were fused [35]. The deletion break point
generated new fusion gene, but it was not translated because of
the complete loss of mitochondrial translation activity by the
absence of several tRNA genes. However, in fused cells, the
fusion protein was observed. It showed that the fusion gene
encoded by deletion mutant mtDNA was translated with the
help of the tRNAs supplied from the HeLa mitochondria,
suggesting unambiguously the occurrence of mitochondrial
complementation.
The idea contradictory to the presence of mitochondrial
complementation has been proposed based on observations that
the coexistence of human respiration-deficient mitochondria
containing different pathogenic mutant mtDNAs derived from
different patients within single cells did not restore reduced
mitochondrial respiratory function [36,37]. The evidence
supporting the absence of mitochondrial complementation
between fused mitochondria is, however, indirect and based
Fig. 1. Restoration of mitochondrial respiratory function. (A) Two cell lines
possess A4269G and A3243G pathogenic mutations tRNAIle and tRNALeu(UUR)
genes, respectively. Both cell lines have no respiratory function. (B) Two cell
lines are fused and hybrids are isolated. (C) Coexistence of mitochondria derived
from these cells enables mitochondrial fusion and following exchange of genetic
contents, including normal tRNAIle and tRNALeu(UUR). (D) mtDNA-encoded
polypeptide synthesis begins with the help of normal tRNA transcribed and
supplied from other mitochondria, followed by restoration of respiratory
function.
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of respiration-deficient ‘parental’ cells grow in nutritional
selection medium without pyruvate and uridine [37] (in which
only cells with restored respiratory function can grow). It is
possible that cybrids are excluded by the selection before
respiratory function can be restored.
The conclusive evidence of mitochondrial complementation
was obtained from fusion of two different types of respiration-
deficient somatic cells caused by different pathogenic mutant
mtDNAs from patients with mitochondrial diseases [38]. At
first, two types of respiration-deficient cell lines were isolated.
They possessed A4269G and A3243G pathogenic mutations in
tRNAIle and tRNALeu(UUR) genes, respectively. Because both cell
lines showed homoplasmy of mutant mtDNAs, they had
decreased translation and no COX activities. The coexistence
of both mitochondria derived from different cell lines within
hybrid cells restored translation and COX activity. This study
showed that at least 10 days of pre-culture before nutritional
selection was required to restore mitochondrial activities.
Moreover, COX electron micrographs showed that the hybrid
cells restored normal mitochondrial morphology and COX
activity by 10–14 days after the fusion. Fusion of the different
types of respiration-deficient mitochondria enables the ex-
change of genetic contents, including normal tRNAIle and
tRNALeu(UUR), resulting in the beginning of mtDNA-encoded
polypeptide synthesis with the help of normal tRNA transcribed
and supplied from other ‘parental’ mitochondria (Fig. 1).
On the other hand, when mutations were created within the
same genes in different mtDNAs, exchange of genetic contents
between mitochondria could not restore respiration deficiency
[39].
3.2. In vivo mitochondrial complementation
In vivo mitochondrial complementation was investigated
using mitochondrial disease model mice, mito-mice [40,41].
They were generated by introduction of respiration-deficient
mitochondria carrying a predominant amount of 4,696 bp
deletion mutant mtDNA (ΔmtDNA) and a residual amount of
wild-type mtDNA from cultured mouse cells into mouse
zygotes [40]. Mito-mice with predominant proportion of
ΔmtDNA showed low body weight, lactic acidosis, systemic
ischaemia, COX deficiency in skeletal and cardiac muscles,
auriculoventricular block with Wenckebach periodicity and
hearing loss. Most of mito-mice died about 6 months after birth
because of renal failure with high blood urea nitrogen and
creatinine levels [40,41].
In mito-mice, COX activity of individual mitochondria in
single cells was examined by COX electron micrographs. COX
electron micrographs clearly showed that all mitochondria in
tissues with ΔmtDNA were COX-positive until ΔmtDNA
became predominant. The appearance of COX-negative mito-
chondria was limited to tissues with more than 85% ΔmtDNA.
Moreover, it was not observed that the coexistence of COX-
positive and COX-negative mitochondria within single cells,
irrespective of whether the tissues contained low or high
concentrations of ΔmtDNA. If exchange of mtDNA did notoccur between exogenous COX-negative mitochondria carrying
ΔmtDNA and COX-positive mitochondria from recipient
zygotes, or even if it occurred, but did not occur frequently and
continuously, mitochondria in the mito-mice would continue to
possess either ΔmtDNA or wild-type mtDNA. Under these
circumstances, cells in tissues with certain ratio of ΔmtDNA
should have the same ratio of COX-negative mitochondria, but
this was not the case [40]. These observations could be explained
by assuming in vivo mitochondrial complementation between
COX-negative mitochondria carrying ΔmtDNA and COX-
positive mitochondria carrying wild-type mtDNA.
The presence of in vivo mitochondrial complementation was
further confirmed by mito-mice possessing ΔmtDNA of Mus
musculus domesticus and wild-type mtDNA of M. spretus [42].
The previous study [41] contained the possibility that
exogenously introduced wild-type mtDNA contributed to the
restoration of COX activity in mito-mice. If it was the case,
the restoration of COX activity observed was not due
to mitochondrial complementation [43]. However, newly
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ΔmtDNA, but not exogenous wild-type mtDNA of M. m.
domesticus to following generations. Complete elimination of
exogenous wild-type mtDNA would be due to stochastic
segregation, whereas transmission of exogenous ΔmtDNA
would be due to its smaller size leading to a propagational
advantage. Tissues in the mito-mice showed complete protec-
tion from respiration deficiency until ΔmtDNA accumulated
predominantly. The coexistence of COX-positive and COX-
negative mitochondria within single cells was not observed.
This protection from expression of mitochondrial dysfunction
was attained by the help of endogenous wild-type mtDNA ofM.
spretus, since the mito-mice did not possess exogenous wild-
type mtDNA of M. m. domesticus. These observations indicate
the presence of complementation between exogenous mito-
chondria carrying ΔmtDNA and endogenous mitochondria
carrying M. spretus wild-type mtDNA.
3.3. mtDNA recombination
Extensive recombination between mtDNAs from both
parental cells has been proved in yeast [44] and plant cells
[45]. Moreover, the presence of recombinant mtDNA was
reported in mussel species [46]. In mammalian species,
however, the issue of mtDNA recombination has been
controversial [47,48]. The activity of enzymes involved in
homologous recombination was identified in mammalian
mitochondria [49]. The presence of recombinant or recombinant
intermediates was suggested by using electrophoresis [50,51].
Some studies suggested the presence of mtDNA recombination
using indirect evidence derived from statistical analyses of
mtDNA sequence data [52–54], although they were criticized
on several grounds [55–58].
Extensive exchanges of mtDNAs between mitochondria in
human hybrid cells [34,35,38] and in mouse tissues [41,42]
suggest exclusion of physical barriers against recombination
between heteroplasmic mtDNAs derived from different indivi-
duals or even from different species. Therefore, this issue could
be resolved by precise sequence analysis of the heteroplasmic
mtDNAs.
Recently, several sequence analyses of PCR products of
heteroplasmic human mtDNAs suggested the presence of
recombination [59–61]. However, studies using PCR for
identification of recombinant mtDNA could not completely
exclude the possibility that artificial recombinants were
generated by PCR jumping [62]. When DNA polymerase
encounters the end of a template molecule, the premature
terminated product jumps to another template and polymer-
ase reaction continues, creating an in vitro recombination
product.
For examination of in vitro mtDNA recombination,
previously generated human hybrid cells possessing A4269G
and A3243G pathogenic mutant mtDNA [38] were used.
Cloning and sequence analysis of the 4878 bp PCR products of
mtDNAs in the hybrid cells was carried out. Of the 100 clones,
64 clones possessed mutation sites specific to parental A3243G
mtDNA and to A4269G mtDNA, suggesting that theycorresponded to recombinant mtDNA. However, cloning and
sequence analysis of mtDNA purified by EtBr-CsCl centrifu-
gation showed no recombinant, suggesting that all recombi-
nants observed in PCR products corresponded to PCR jumping
products [63].
For examination of in vivo mtDNA recombination, mito-
mouse possessing ΔmtDNA ofM. m. domesticus and wild-type
mtDNA of M. spretus [42] were used. To avoid PCR jumping
artifacts, PCR products were not used, but mtDNAs purified
from mito-mouse tissues by EtBr-CsCl centrifugation were used
for cloning and sequence analysis. Of the 318 clones, only three
clones possessed M. m. domesticus and M. spretus mtDNA
specific mutation sites [63].
Considering the high concentration of ROS around the
mtDNA and its frequent strand breakage, recombinant clones
would correspond to gene conversion products created by repair
of nucleotide mismatches.
The presence of recombinant mtDNA indicates that the exo-
and endogenous mtDNAs come into close enough proximity to
convert their sequences.
4. Gene therapy for mitochondrial diseases
The presence of extensive and continuous complementation
between fused mitochondria could correspond to a unique
defense system to compensate for defects induced by various
kinds of mtDNA mutations, regardless of whether they are
transmitted maternally [41,42] or are newly acquired [25–28].
The system is also applied to gene therapy for mitochondrial
diseases. When normal mitochondria with wild-type mtDNA
are introduced into cells with mutant mtDNA, cellular
respiration activity would be restored by mitochondrial
complementation. The issue of gene therapy for mitochondrial
diseases was addressed using zygotes of mito-mice [40]. Since
inheritance of mtDNA is strictly maternal [64–66], gene
therapy of zygotes would be effective procedure to obtain
normal progeny.
4.1. Preimplantation genetic diagnosis
Before treatment, the preimplantation genetic diagnosis of
mitochondrial disease was important [67]. Because mtDNA is
distributed randomly to the offspring, it is possible that the
offspring would possess various proportions of mutant mtDNA.
Moreover, bottleneck effect, reduction of mtDNA copy number
in primordial germ cells, is thought to contribute to rapid
mtDNA segregation [68,69].
It is important whether the proportion of mutant mtDNA in
biopsy samples used for preimplantation genetic diagnosis
correlates with that of embryos or individuals. In human fetuses
or neonates with pathogenic mutant mtDNAs, it was suggested
that mtDNA did not segregate much during embryogenesis
[70,71]. In preimplantation embryos, polar bodies and blas-
tomeres were shown to be effective for deducing the status of
heteroplasmy in embryos of mice carrying NZB and BALB
wild-type mtDNAs [72]. Also, in mito-mice possessing
pathogenic ΔmtDNA, the proportions of ΔmtDNA in zygotes
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were used as biopsy samples of zygotes.
In mito-mice, expression of disease phenotype is strictly
dependent on proportion of ΔmtDNA [40,41]. In human, it is
well known that deletion mutant mtDNAs possess replication
advantages over wild-type mtDNA due to its smaller size
[24,74,75]. In mito-mice, ΔmtDNA also possesses replication
advantages, and it leads to ΔmtDNA accumulation during
aging. Thus, for success of preimplantation genetic diagnosis,
the change of ΔmtDNA proportions during in utero develop-
ment, postnatal stage and aging should be addressed.
When the proportions of ΔmtDNA in the polar bodies of
zygotes and whole bodies of neonates developed from the same
zygotes were compared, the zygotes used possessed 2–78%
ΔmtDNA in their polar bodies, and the resultant neonatesFig. 2. Schematic representation of gene therapy. Polar bodies of mito-mouse zygot
zygotes with more than 5% ΔmtDNA die because of respiration deficiency. Male an
enucleated normal zygotes by electrofusion. Small amount of mitochondria with Δ
possess low levels of ΔmtDNA and expression of disease phenotypes is prevented.possessed 0–75% ΔmtDNA. No neonates developed from
zygotes carrying more than 60% ΔmtDNA. Considering that
the average increase in the proportion of ΔmtDNA during
gestation (for 19 days) was 17±10% (mean±S.D.), neonates
developed from such zygotes possessing more than 60%
ΔmtDNA would carry more than 77% ΔmtDNA during
gestation, and would be lethal in the uterus.
The following increase rate of ΔmtDNA proportion in mito-
mice tails was 17% during gestation (19 days after fertilization),
8% before weaning after birth (for 30 days after birth), 8% in the
first 100 days after weaning, and 6% in every subsequent 100
day period. The significant decrease in the rate of ΔmtDNA
accumulation after birth would correspond to decrease of the
mtDNA replication frequency due to decrease in frequency of
cell division [72].es are used to estimate the proportion of ΔmtDNA. Mito-mice developed from
d female pronuclei are enucleated from mito-mouse zygotes and introduced into
mtDNA are cointroduced into normal zygotes. Nuclear-transplanted mito-mice
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possessing more than 80% ΔmtDNA [40,41] and the rate of
ΔmtDNA accumulation, mito-mice carrying less than 5%
ΔmtDNA at their zygote stage can avoid expression of disease
phenotypes caused byΔmtDNA-induced respiration deficiency
within their life times.
4.2. Gene therapy of mito-mice by nuclear transplantation
Effective procedures to obtain normal progeny from affected
mothers would be either nuclear transplantation from mito-
mouse zygotes to enucleated normal zygotes, or cytoplasmic
transplantation of mitochondria from normal to mito-mouse
zygotes [67,76]. Ooplasmic transfer has been used as an
effective technique to restore normal developmental potential of
oocytes from patients with embryonic development failure
[77,78]. However, the amount of mtDNA copies that could be
introduced into mouse zygotes by cytoplasmic transplantation is
relatively small. Nuclear transplantation inevitably cointroduces
a small volume of cytoplasm and mitochondria, but the amount
of mtDNA cointroduced with nucleus is 6% of all mtDNA in
zygotes [73]. Nuclear transplantation would result in production
of zygotes with less than 5% ΔmtDNA from mito-mice, even
when the mito-mouse zygotes possess the maximum proportion
of ΔmtDNA (78%). It indicates that we can prevent all progeny
of mito-mice from expression of disease phenotypes. Then,
nuclear transplantation was considered to be more effective than
cytoplasmic transplantation for sufficient dilution of ΔmtDNA
in zygotes of mito-mice (Fig. 2).
First, proportions ΔmtDNA in mito-mouse zygotes were
estimated using polar bodies as biopsy samples. Next, from 39
zygotes possessing 35±7% ΔmtDNA, karyoplasts were
prepared and fused with enucleated normal zygotes. They
were transferred to pseudopregnant females, and the resultant
11 mice at the weaned stage possessed 11±5% ΔmtDNA in
their tails. On the other hand, when 34 mito-mouse zygotes with
32±12% ΔmtDNAwere transferred without nuclear transplan-
tation, obtained 9 mice possessed 66±9% ΔmtDNA. They
showed respiration deficiency and died because of renal failure
at 218–277 days after birth, while nuclear-transplanted mito-
mice showed no abnormalities throughout their lives [73].
Recently, it was reported that the UK Human Fertilization
and Embryology Authority (HFEA) would allow scientists at
the University of Newcastle upon Tyne to transfer the nucleus of
a human fertilized egg into an egg donated by a second woman.
The study using mito-mice unambiguously showed that the
technique could also be applied to human patients with
mitochondrial diseases.
In human cases, however, there are several problems to be
resolved before applying gene therapy to zygotes. One is that
human unfertilized oocytes, but not zygotes, are preferable for
nuclear transplantation. When unfertilized oocytes are used for
nuclear transplantation, following in vitro fertilization with
partner's sperm should be carried out as suggested by Thorburn
and Dahl [76].
Another problem is that maternal transmission of deletion
mutant mtDNA is rare in human [79,80]. When deletion mutantmtDNA is transmitted to oocytes [81], the 13 times longer
gestation period in humans than in mice would result in
accumulation of a sufficient proportion of deletion mutant
mtDNA in nuclear-transplanted embryos to be lethal before
birth. Therefore, application of nuclear transplantation would be
restricted to patients with mitochondrial diseases, only when
pathogenic mtDNAs in patients were inherited maternally, and
did not possess significant replication advantages over wild-
type mtDNA. For example, zygotes from patients with MELAS
and MERRF caused by 3243 and 8344 point mutations in
mtDNAs, respectively, would be appropriate for applying
nuclear transplantation to rescue their F0 progeny. In these
cases, a small proportion of wild-type mtDNAs was sufficient to
suppress disease phenotypes [82,83].
An additional biological problem is that nuclear transplan-
tation results in zygotes possess nuclear genomes from both
parents but possess mitochondrial genomes from normal donors.
Moreover, there was no evidence and no rational explanation
that the heteroplasmic state itself or resultant creation of mtDNA
recombinants induced respiration deficiency.
Recently, Spees et al. demonstrated adult nonhematopoietic
stem/progenitor cells from human bone marrow or fibroblast
rendered mitochondria into ρ° cells when they were cocultured
[84]. If such a transfer of mitochondria is also possible in vivo,
adult mito-mice can be rescued.
5. Accelerated aging and mtDNA mutations
Recently, Trifunovic et al. [85] and Kujoth et al. [86]
addressed the mitochondrial theory of aging by creating
knock-in mice “mutator mice” expressing a proofreading-
deficient version of the mitochondrial DNA polymerase γ
(POLG). The mutator mice showed increased levels (3–
8 times) of mtDNA mutations, premature aging phenotypes,
such as reduced lifespan, weight loss, hair loss, curvature of
the spine, loss of bone mass, decrease in red blood cells and
testicular atrophy [85,86], and no increase of ROS production
[86,87]. Although ROS has been thought to be the major
contributor of the aging, their findings indicated the
premature aging phenotypes were not caused by increase of
oxidative stress accompanied by accumulation of mtDNA
mutations [86–88].
There are several different phenotypes between the mutator
mice created by the two groups, although the same amino acid
residue was substituted. First, Kujoth et al. [86] showed
increased levels of caspase-3, key mediator of apoptosis, and
TUNEL (terminal deoxynucleotidyl transferase-mediated deox-
yuridine triphosphate nick end labeling)-positive cells in several
tissues of mutator mice. They suggested that the increased
apoptosis caused premature aging phenotypes. On the other
hand, Trifunovic et al. showed no increased sensitivity to
oxidative stress induced apoptosis in mouse embryonic
fibroblasts (MEFs) [87]. Second, Trifunovic et al. showed
progressive reduction of respiratory function and ATP produc-
tion rates [85,87] but Kujoth et al. did not [86]. Trifunovic et al.
associated the respiration deficiency with the premature aging
phenotypes [85]. However, random mutation occurred in
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presence of mitochondrial interaction. Thus, even though clonal
accumulation of mutant mtDNA in each cell is indispensable for
respiratory dysfunction, Trifunovic et al. showed no evidence
for clonal accumulation of certain mutant mtDNA both in adult
mutator mice [85] and MEFs [87]. It is ambiguous whether
mitochondria are contributing to the premature aging
phenotypes.
6. Conclusions
The mitochondrial theory of aging proposes that age-
associated accumulation of somatic mutations in mtDNAs is
responsible for age-associated mitochondrial dysfunction. In
fact, mtDNA is continuously exposed to ROS generated in
mitochondria and accumulation of various kinds of mtDNA
mutations was reported. However, the mitochondrial theory of
aging is based on the circumstantial evidence. Random somatic
mtDNA mutations are complemented by exchange of mtDNAs
and its products. This mitochondrial complementation is a very
unique and effective defense system of the highly oxidative
organelles for preventing individuals from expression of
respiratory deficiency caused by mutant mtDNAs.
It is generally accepted that mitochondria are the symbionts
into eukaryotic cells. After the symbiosis, mitochondria might
have lost individuality due to the development of mitochondrial
complementation. Thus, mitochondria function as a single
cellular unit in mammalian cells.
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